South african dyslipidaemia guideline consensus statement

South African Medical Journal

Volumn 102, Issue 3, 2012, Pages 178-188

  Klug, E Q ^a   Raal, F J ^a   Marais, A D ^a   Taskinen, M R ^a   Dalby, A J ^a   Schamroth, C ^a   Rapeport, N ^a   Jankelow, D ^a   Blom, D J ^a   Catsicas, R ^a   Webb, D A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTIRETROVIRUS AGENT; ATORVASTATIN; BILE ACID SEQUESTRANT; C REACTIVE PROTEIN; CHOLESTEROL; DILTIAZEM; EZETIMIBE PLUS SIMVASTATIN; FLUINDOSTATIN; GESTAGEN; HYPOCHOLESTEROLEMIC AGENT; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; RETINOID; ROSUVASTATIN; SIMVASTATIN; STATIN; STEROID; VERAPAMIL;

ACUTE CORONARY SYNDROME; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CONSENSUS; CORONARY ARTERY DISEASE; DIET SUPPLEMENTATION; DRUG MEGADOSE; DYSLIPIDEMIA; FRAMINGHAM RISK SCORE; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPOCHOLESTEROLEMIA; LIFESTYLE MODIFICATION; LIPID ANALYSIS; LOW DRUG DOSE; METABOLIC SYNDROME X; MICROALBUMINURIA; MYALGIA; MYOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; POINT OF CARE TESTING; PRACTICE GUIDELINE; PROTEINURIA; RHABDOMYOLYSIS; RISK ASSESSMENT; SCREENING; SIDE EFFECT; SOUTH AFRICA; TRIACYLGLYCEROL BLOOD LEVEL;

CHOLESTEROL, LDL; DIETARY SUPPLEMENTS; DISEASE MANAGEMENT; DYSLIPIDEMIAS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIFE STYLE; RISK ASSESSMENT; RISK REDUCTION BEHAVIOR; SOUTH AFRICA;

EID: 84857678459     PISSN: 02569574     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. De Backer G, Ambrosioni E, Borch-Johnson K, et al. European guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2003;24:1601-1610.
2. South African Medical Association and Lipid and Atherosclerosis Society of Southern Africa Working Group. Diagnosis, management and prevention of the common dyslipidaemias in South Africa-Clinical Guideline, 2000. S Afr Med J 2000;90:164-178.
3. Reiner Ž, Catapano AL, De Backer G, et al, For the Task Force for the management of dyslipidaemias of the European Society for Cardiology (ESC) and the European Atherosclerosis Society (EAS). ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J 2011;32:1769-1818.
4. Steyn K. Heart disease in South Africa. Media data document. Heart and Stroke Foundation South Africa, July 2007.
5. Steyn K, Sliwa K, Hawken S, et al. Risk factors associated with myocardial infarction in Africa. The INTERHEART Africa Study. Circulation 2005;112:3554-3561.
6. Yusuf S, Hawken S, Ounpuu S. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004;364(9438):937-952.
7. National Institutes of Health, National Heart, Lung & Blood Institute. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High blood Cholesterol in Adults (Adult Treatment Panel III). Executive Summary. NIH Publication No. 01-3670, May 2001. Bethesda, Md, 2001.
8. Mosca L, Benjamin EJ, Berra K, et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women 2011 update: A guideline from the American Heart Association. Circulation 2011;123:1243-1262.
9. D'Agostino RB, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008;117:743-753.
10. Batki AD, Nayyar P, Thomason HL. Buyer's guide: Point-of-care testing for cholesterol measurement. NHS Purchasing and Supply Agency. Center for Evidence-based Purchasing. CEP 09020; September 2009. http://www.healthcheck.nhs.uk/Library/pointofcare_testing_for_cholesterol_measurement.pdf (accessed 26 October 2011).
11. Sacks F, Bray GA, Carey VJ, et al. Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates. N Engl J Med 2009;360(9):859-873.
12. Violi I F, Pignatelli P, Basili S. et al. Nutrition, supplements and vitamins in platelet functions and bleeding. Circulation 2010;121:1033-1044.
13. Mursu J, Robien K, Harnack LJ, et al. Dietary supplements and mortality rate in older women. The IOWA Women's Health Study. Arch Intern Med 2011;171(18):1625-1633.
14. Marcoff L, Thompson PD. The role of coenzyme Q10 in statin-associated myopathy. A systematic review. J Am Coll Cardiol 2007;49(23):2231-2237.
15. Schaars CF, Stalenhoef AFH. Effects of ubiquinone (coenzyme Q10) on myopathy in statin users. Curr Opin Lipidol 2008;19:553-557.
16. Egan A, Coleman E. Weighing the benefits of high-dose simvastatin against the risk of myopathy. N Engl J Med 2011;365(4):285-287.
17. Eckel RH. Approach to the patient who is intolerant of statin therapy. J Clin Endocrinol Metab 2010;95(5):2015-2022.
18. Preiss D, Seshasai SRK, Welsh P, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy. JAMA 2011;305(24):2556-2564.
19. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010;375(9716):735-742.
20. Rajpathak SN, Kumbhani DJ, Crandall J, et al. Statin therapy and risk of developing type 2 diabetes: A meta-analysis. Diab Care 2009;32:1924-1929.
21. Weng T-C, Kao Yang Y-H, Lin S-J, et al. A systematic review and meta-analysis on the therapeutic equivalence of statins. J Clin Pharm Ther 2010;35:139-151.
22. Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomized placebo controlled trial. Lancet 2011;377:2181-2181.
23. Alberti KGMM, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome. A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009;120:1640-1645.